#### Supplements

|  |  |
| --- | --- |
| Characteristic | Mean ± SD (range) / n [%] |
| Age [years] | 31.85 ± 5.31 (20-46) |
| Gravida | 1.99 ± 1.37 (1-8) |
| Para | 1.67 ± 0.95 (1-5) |
| Gestational age at diagnostic  | 30.57 ± 5.58 (11-40) |
| BMI at delivery  | 30.15 ± 7.00 (19-54) |
| BMI before pregnancy  | 26.35 ± 6.60 (15-49) |
| PI A. uterina right  | 1.19 ± 0.65 (0.29-3.51) |
| PI A. uterina left  | 1.28 ± 0.63 (0.29-3.49) |
| CPR  | 1.57 ± 0,57 (0.28-3.20) |
| systolic blood pressure [mmHg] | 138.92 ± 23.68 (85-210) |
| Mean arterial pressure (MAP) [mmHg] | 101.78 ± 17.50 (62-160) |
| prophylactic Aspirin intake | 46 (22.3 %)  |
| Smoker  | 14 (6.8 %) |
| German ethnicity | 183 (88.8 %)  |
| Vaginal delivery (most Labor induction) | 58 (14.1 %) |
| Caesarean sections CS | 129 (62.6 %) |
| GDM | 29 (14.1 %) |
| birthweight under the 10th centile | 72.6 % |
| birthweight [g] | 2080.34 ± 985.73 (185-4670) |
| gestational age at delivery | 33.50 ± 4.49 (20-41) |
| Deliveries before the 37th pregnancy week | 137 (66.5 %)  |
| Umbilical arterial pH | 7.29 ± 0.08 (6.96-7.43) |
| Umbilical venous pH | 7.35 ± 0.15 (6.97-9.00) |
| Fetal sex female | 89 (43.2 %) |
| NICU admission | 147 (71.4 %)  |
| Dead in the perinatal period  | 8 (3.9 %) |
| Intrauterine demise | 7 (3.4 %) |
| sFlt/PLGF Ratio  | 537.14 ± 713.16 (0.09-4177.14) |
| soluble Endoglin [ng/ml] | 62.74 ± 61.23 (4.08-337.12) |

###### Tab. A1 Clinical characteristics and outcome of the whole study population

|  |  |  |
| --- | --- | --- |
| Outcome | n | rel. frequency [%] |
| PE, no IUGR or HELLP | 37 | 18.1 |
| PE and IUGR, no HELLP | 32 | 15.7 |
| HELLP, no PE or IUGR | 6 | 2.9 |
| IUGR, no PE or HELLP | 40 | 19.6 |
| no PE, IUGR, or HELLP | 60 | 29.4 |
| PE and HELLP, no IUGR | 11 | 5.4 |
| IUGR and HELLP, no PE | 4 | 2.0 |
| PE, IUGR, and HELLP | 14 | 6.9 |

###### Table A2: Overlap between outcome groups.

|  |  |  |  |
| --- | --- | --- | --- |
|  | aOR | Lower CL 95% | Upper CL 95% |
| *sflt 1/PlGF* |  |  |  |
| PE | 2,692 | 1,859 | 3,895 |
| IUGR | 2,389 | 1,642 | 3,444 |
| HELLP | 2,103 | 1,451 | 3,045 |
| Placental dysfunction | 2,380 | 1,859 | 3,444 |
| *sEndoglin* |  |  |  |
| PE | 2,330 | 1,589 | 3,478 |
| IUGR | 2,275 | 1,551 | 3,398 |
| HELLP | 1,880 | 1,451 | 3,045 |
| Placental dysfunction | 2,502 | 1,749 | 3,819 |
| *sFlt* |  |  |  |
|  |  |  |  |
| PE | 7,242 | 3,677 | 14,263 |
| IUGR | 6,928 | 3,514 | 13,658 |
| HELLP | 6,021 | 2,798 | 12,956 |
| *PLGF* |  |  |  |
| PE | 0,993 | 0,988 | 0,996 |
| IUGR | 0.994 | 0,991 | 0,996 |
| HELLP | 0,989 | 0,977 | 0,995 |

###### Table A: Odd Ratios and corresponding 95% confidence intervals (95% CI) between pregnancy outcomes (PE, IUGR, HELLP) and angiogenic factors (sFlt-1, PIGF, sFlt1/PlGF Ratio, and sEng), adjusted by the maternal age, the gestational week at the blood sampling and the maternal BMI. All associations were statistically significant at a p-value of < 0.0001.